Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, Jaeger E, Aichberger KJ, Ott RG, Greish K, Nakamura H, Derdak S, Samorapoompichit P, Pickl WF, Sexl V, Esterbauer H, Schwarzinger I, Sillaber C, Maeda H, Valent P. Mayerhofer M, et al. Among authors: aichberger kj. Blood. 2008 Feb 15;111(4):2200-10. doi: 10.1182/blood-2006-11-055723. Epub 2007 Nov 16. Blood. 2008. PMID: 18024796 Free article.
CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.
Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P. Sotlar K, et al. Among authors: aichberger kj. Am J Surg Pathol. 2004 Oct;28(10):1319-25. doi: 10.1097/01.pas.0000138181.89743.7b. Am J Surg Pathol. 2004. PMID: 15371947
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C. Aichberger KJ, et al. Blood. 2005 Apr 15;105(8):3303-11. doi: 10.1182/blood-2004-02-0749. Epub 2004 Dec 30. Blood. 2005. PMID: 15626746 Free article.
Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPalpha), CD47, and SHP-1.
Florian S, Ghannadan M, Mayerhofer M, Aichberger KJ, Hauswirth AW, Schernthaner GH, Printz D, Fritsch G, Böhm A, Sonneck K, Krauth MT, Müller MR, Sillaber C, Sperr WR, Bühring HJ, Valent P. Florian S, et al. Among authors: aichberger kj. J Leukoc Biol. 2005 Jun;77(6):984-92. doi: 10.1189/jlb.0604349. Epub 2005 Mar 22. J Leukoc Biol. 2005. PMID: 15784688
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P. Mayerhofer M, et al. Among authors: aichberger kj. FASEB J. 2005 Jun;19(8):960-2. doi: 10.1096/fj.04-1973fje. Epub 2005 Mar 22. FASEB J. 2005. PMID: 15784722
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Gleixner KV, et al. Among authors: aichberger kj. Blood. 2006 Jan 15;107(2):752-9. doi: 10.1182/blood-2005-07-3022. Epub 2005 Sep 27. Blood. 2006. PMID: 16189265 Free article.
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P. Aichberger KJ, et al. Cancer Res. 2005 Oct 15;65(20):9436-44. doi: 10.1158/0008-5472.CAN-05-0972. Cancer Res. 2005. PMID: 16230407
42 results